We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Synthetic Antibody Demonstrates Omicron Detection
Product News

Synthetic Antibody Demonstrates Omicron Detection

Synthetic Antibody Demonstrates Omicron Detection
Product News

Synthetic Antibody Demonstrates Omicron Detection


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Synthetic Antibody Demonstrates Omicron Detection "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MIP Diagnostics Ltd. has announced that its synthetic SARS-CoV-2 antibody (COVID-19 nanoMIPTM) can detect the Omicron variant as well as previously proven Alpha, Beta, Delta and Gamma variants of the COVID-19 virus.


MIP Diagnostics, the leading manufacturer of molecularly imprinted polymers (MIPs) -  commonly termed synthetic antibodies -  has demonstrated that its COVID-19 nanoMIPTM can detect the increasingly dominant Omicron variant. The synthetic antibody has already been shown to detect the other variants of concern - Alpha, Beta, Delta and Gamma.


Initial assessment using pharmaceutical grade molecular modelling software demonstrated the COVID-19 nanoMIPTM should be able to detect the Omicron variant, and this has now been confirmed via laboratory testing. The COVID-19 nanoMIPTM was shown to detect the SARS-CoV-2 Omicron variant spike protein (Native Antigen Company) in buffer using surface plasmon resonance (SPR), with a magnitude of specific response comparable to other variants of the virus previously tested. Third party validation in a separate sensor device will be carried out shortly. 


Originally developed in under 8 weeks, the MIP Diagnostics COVID-19 nanoMIPTM offers IVD manufacturers a host of benefits including high selectivity and sensitivity demonstrated to the picogram level in a number of COVID-19 sensor devices. The robust nature of MIPs, when compared to antibodies, will also provide the superior shelf life and storage properties required by the IVD market as self-testing becomes more prevalent across multiple disease states following the COVID-19 pandemic.


Speaking on the new data, Alan Thomson, CTO at MIP Diagnostics said, “In pandemic situations, a fast response is essential, and our advanced molecular modeling software had already been utilised to assess the performance of the COVID-19 nanoMIP against the Omicron variant in-silico. This new data has confirmed our initial findings, and not only demonstrates the capabilities of the COVID-19 nanoMIP, but also supports the wider progress toward robust, non-animal derived reagents in the IVD industry.”

  

Advertisement